Medpace manages clinical trials for small biotech companies.
Medpace Holdings, Inc. (MEDP) is expected to report earnings on Wednesday, October 28, 2026, after the close. Estimated release time 16:15 ET. Consensus EPS estimate is $4.39.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-22 | FY2026 Q2 | $3.98 | $4.25 | +6.8% | $707.33M |
| 2026-04-22 | FY2026 Q1 | $3.92 | $4.28 | +9.2% | $706.60M |
| 2026-02-09 | FY2025 Q4 | $4.19 | $4.67 | +11.5% | $708.45M |
| 2025-10-22 | FY2025 Q3 | $3.53 | $3.86 | +9.3% | $659.90M |
| 2025-07-21 | FY2025 Q2 | $2.98 | $3.10 | +4.0% | $603.31M |
| 2025-04-21 | FY2025 Q1 | $3.06 | $3.67 | +19.9% | $558.57M |
| 2025-02-10 | FY2024 Q4 | $2.96 | $3.67 | +24.0% | $536.59M |
| 2024-10-21 | FY2024 Q3 | $2.78 | $3.01 | +8.3% | $533.32M |
MEDP has beaten consensus EPS in 8 of its last 8 reported quarters.
Highlights from MEDP's Jul 22 report: EPS of $4.25 — a beat vs the $3.98 estimate (+7%); revenue of $707M — a beat vs the $690M consensus (+3%). Focus now shifts to backlog conversion and biotech funding.
See MEDP on the live calendar →